semaglutide safety concerns A Critical Eye on GLP-1 Receptor Agonists The FDA's Decision to Ban

Based on the research and clinical trials, here are the disease states and associated risk reductions with GLP-1 medications: Cardiovascular Disease: Major adverse cardiovascular events (MACE): 20-26% reduction Heart attack: ~20% reduction Stroke: ~20% reduction Cardiovascular death: ~15-20% reduction Heart Failure: Heart failure with preserved ejection fraction (HFpEF): Improved symptoms, exercise tolerance, and body composition Heart failure hospitalizations: Reduced (specific percentages vary by study) Kidney Disease: Progression to end-stage renal disease: 20-30% reduction Decline in eGFR: Slowed progression Type 2 Diabetes: Progression from prediabetes to diabetes: Reduced risk (specific percentage varies) Liver Disease: NAFLD/NASH improvement: Reduced liver fat and inflammation Liver enzyme normalization: Significant improvement in ALT/AST Obesity-Related Complications: Body weight reduction: 10-15% (semaglutide), 15-22% (tirzepatide) Visceral fat reduction: Substantial decrease Metabolic Syndrome Components: Blood pressure: 5-10 mmHg reduction in systolic BP Triglycerides: 20-30% reduction Insulin resistance: Significant improvement Cancer: (emerging data) Overall cancer risk: Potential reduction (10-20% suggested in some observational studies) Specific cancers linked to obesity/metabolic dysfunction: Reduced risk observed Neurodegeneration: (preliminary data) Alzheimers disease progression: Some trials are ongoing, but recent data have been unpromising

[5] Additionally, gastric electrical stimulation (GES

The co-primary endpoints were analysed separately using linear normal models on log 10 -transformed data, including treatment as a fixed effect and baseline value as a covariate

Cc li ch chnh ca sn phm: Lm sng da v u mu da : Glutathione gip gim thm nm, tn nhang, ng thi lm sng da, mang li ln da u mu v rng r

Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases

Ipamorelin is a selective ghrelin / GHS-R agonist (a growth-hormone-releasing peptide, GHRP)